X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
IPCA LABORATORIES LIMITED Fact Sheet - Equitymaster
Investing in India? Get Equitymaster Research  

IPCA LABORATORIES LIMITED  (IPLB)


Here is the latest financial fact sheet of IPCA Labs. For more details, see the IPCA Labs quarterly results and IPCA Labs share price and chart. For a sector overview, read our pharmaceuticals sector report.
 
ipca labs - 1 Year Stock Price Chart
Loading...

 Price History
    Price Rs 598.9       No. of shares m 126.20
    Mkt Cap Rs m 75,581       % ch % 0.7
    Vol '000 19.3       % ch week % -2.0
    P/E X 50.3       % ch 1-mth % 8.6
    P/CF X 28.1       % ch 12-mth % 21.1
    EPS (TTM) Rs 11.9       52 week H/L Rs 656.0/402.0
(As on Apr 21, 2017 (Close)) »  Best Performing pharmaceuticals Stocks

Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!
 Financials

* Results Consolidated
No. of Months
Year Ending
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
5-Yr Chart
Click to enlarge
  EQUITY SHARE DATA
High Rs352567907899888 
Low Rs230320541591629 
Sales per share (Unadj.) Rs187.0222.9260.0249.2228.6 
Earnings per share (Unadj.) Rs22.025.637.920.17.4 
Diluted earnings per shareRs22.025.637.920.17.4 
Cash flow per share (Unadj.) Rs27.332.546.134.421.0 
Dividends per share (Unadj.) Rs3.204.005.001.000 
Adj. dividends per shareRs3.204.005.001.000.00 
Dividend yield (eoy) %1.10.90.70.10 
Book value per share (Unadj.) Rs99.4123.1155.3175.0181.0 
Adj. book value per shareRs99.4123.1155.3175.0181.0 
Shares outstanding (eoy) m126.15126.20126.20126.20126.20 
Bonus/Rights/Conversions  ESOSESOS--- 
Price / Sales ratio x1.62.02.83.03.3 
Avg P/E ratio x13.217.319.137.0102.6 
P/CF ratio (eoy) x10.713.615.721.736.1 
Price / Book Value ratio x2.93.64.74.34.2 
Dividend payout %14.615.613.25.00 
Avg Mkt Cap Rs m36,71055,97091,35694,05795,723 
No. of employees `0009.810.911.713.013.1 
Total wages/salary Rs m3,3553,9184,9805,6516,270 
Avg. sales/employee Rs Th2,403.92,578.72,798.52,416.42,197.0 
Avg. wages/employee Rs Th341.8359.1424.7434.3477.4 
Avg. net profit/employee Rs Th282.3296.6408.1195.471.0 
  INCOME DATA
Net Sales Rs m23,59428,13132,81831,44428,850 
Other income Rs m120143223327169 
Total revenues Rs m23,71428,27433,04031,77129,020 
Gross profit Rs m4,5995,6017,3835,3633,022 
Depreciation Rs m6718671,0311,7961,722 
Interest Rs m413334269284316 
Profit before tax Rs m3,6344,5436,3063,6111,153 
Minority Interest Rs m00000 
Prior Period Items Rs m9-83-49-35 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m8721,2991,5241,019186 
Profit after tax Rs m2,7713,2364,7852,542933 
Gross profit margin %19.519.922.517.110.5 
Effective tax rate %24.028.624.228.216.1 
Net profit margin %11.711.514.68.13.2 
  BALANCE SHEET DATA
Current assets Rs m12,10013,97216,01416,14015,577 
Current liabilities Rs m6,4026,3377,9159,0448,599 
Net working cap to sales %24.227.124.722.624.2 
Current ratio x1.92.22.01.81.8 
Inventory Days Days1049694108107 
Debtors Days Days5354504148 
Net fixed assets Rs m10,15012,09814,84120,33231,134 
Share capital Rs m252252252252252 
"Free" reserves Rs m11,84715,05119,09821,56422,552 
Net worth Rs m12,54015,53819,59722,08422,838 
Long term debt Rs m3,3023,6622,9405,0324,883 
Total assets Rs m23,27326,97032,10638,12438,259 
Interest coverage x9.814.624.513.74.6 
Debt to equity ratio x0.30.20.20.20.2 
Sales to assets ratio x1.01.01.00.80.8 
Return on assets %13.713.215.77.43.3 
Return on equity %22.120.824.411.54.1 
Return on capital %25.625.429.214.25.2 
Exports to sales %57.459.260.452.947.4 
Imports to sales %18.815.016.116.79.9 
Exports (fob) Rs m13,53416,66719,83616,62413,678 
Imports (cif) Rs m4,4314,2215,2825,2472,870 
Fx inflow Rs m13,60916,76620,04816,74913,744 
Fx outflow Rs m5,7515,8047,2726,9564,445 
Net fx Rs m7,85910,96212,7769,7939,299 
  CASH FLOW
From Operations Rs m 3,538 3,888 5,223 4,682 4,915 
From Investments Rs m -2,859 -2,599 -3,690 -6,893 -2,086 
From Financial Activity Rs m -718 -829 -1,361 2,505 -2,123 
Net Cashflow Rs m -39 460 172 294 706 
* Results Consolidated Source: Company Annual Reports, Regulatory Filings, Equitymaster »  Historical quarterly results for ipca laboratories limited

 Share Holding
Indian Promoters : 45.9%
Foreign collaborators : 0.0%
Indian inst/Mut Fund : 11.4%
FIIs : 25.3%
ADR/GDR : 0.0%
Free float : 17.4%
Shareholders : 36,892
Pledged promoter(s) holding : 2.1%
 Company Information
Top
    REGD OFF: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai - 400 067
    E-MAIL: investors@ipca.com     WEB: www.ipca.com
    TELEPHONE: (022) 6647 4444     FAX: (022) 2868 6613
    SECTOR: PHARMACEUTICALS     GROUP: MISCELLANEOUS
    TR AGENT: Link Intime India, C13, Pannalal Silk Mills Cmpd., LBS Marg, Mumbai-78
    AUDITOR: Natvarlal Vepari & Co.
CHM: Premchand Godha (MD) COMP SEC: Harish P. Kamath (VP - Legal) YEAR OF INC: 1949 BSE CODE: 524494 FV (Rs): 2 DIV YIELD (%): -

More pharmaceuticals Company Fact Sheets:   NOVARTISJ.B.CHEMICALSDR. REDDYS LABPLETHICO PHARMAINDRAPRASTHA MEDICAL


Today's Market

French Presidential election and Oil Price Fall Impact Global Markets(RoundUp)

Investors were cautious ahead of the first round of the French Presidential elections ending next week. Fall in crude oil prices amidst oversupply concerns also adversely affected Global markets this week.

Views on news

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

More Views on News

Most Popular

Our Private Class with India's Value Investing Guru(The 5 Minute Wrapup)

Apr 19, 2017

Rohan and Kunal present you the discussions with professor Sanjay Bakshi in his virtual classroom.

Why Suddenly There is No Cash in ATMs(Vivek Kaul's Diary)

Apr 11, 2017

There have been a spate of media reports around ATMs not dispensing cash. What is really happening here?

HDFC Bank: The Solid Outperformer(Chart Of The Day)

Apr 22, 2017

Why HDFC Bank beat the Sensex by nearly 3 times.

The Real Reason Indiabulls Real Estate Jumped 42%(Daily Profit Hunter)

Apr 19, 2017

An elephant and six blind men will tell you more about the markets than any financial newspaper or channel.

Is PPF As An Investment Avenue Dead?(Outside View)

Apr 11, 2017

It's true, the interest on PPF has been lowered to 7.9%. PersonalFN evaluates if it's still a promising investment avenue.

More

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON IPCA LABS

IPCA LABS 8-QTR ANALYSIS

Detailed Quarterly Results With Charts

COMPARE IPCA LABS WITH

MARKET STATS